SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial
SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial
Background: in children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma.
Methods: this phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial.
Results: the rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group.
Conclusion: as a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.
allergen immunotherapy, allergic asthma, children, house dust mite, sublingual immunotherapy
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Just, Jocelyne
ae1fd282-3151-40c8-810b-5d57988e305b
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hels, Ole Holm
14f248e4-fe2d-4f78-9a5c-5345e79caaf5
Emeryk, Andrzej
314abef7-2651-48a8-9303-82f906889b58
Vidal, Carmen
6728932c-8094-40a8-87d5-8e27d7781722
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Just, Jocelyne
ae1fd282-3151-40c8-810b-5d57988e305b
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hels, Ole Holm
14f248e4-fe2d-4f78-9a5c-5345e79caaf5
Emeryk, Andrzej
314abef7-2651-48a8-9303-82f906889b58
Vidal, Carmen
6728932c-8094-40a8-87d5-8e27d7781722
Roberts, Graham, Just, Jocelyne, Nolte, Hendrik, Hels, Ole Holm, Emeryk, Andrzej and Vidal, Carmen
(2025)
SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial.
Allergy.
(doi:10.1111/all.70073).
Abstract
Background: in children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma.
Methods: this phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial.
Results: the rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group.
Conclusion: as a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.
Text
Allergy - 2025 - Roberts - SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma A
- Version of Record
More information
Accepted/In Press date: 15 August 2025
e-pub ahead of print date: 9 October 2025
Keywords:
allergen immunotherapy, allergic asthma, children, house dust mite, sublingual immunotherapy
Identifiers
Local EPrints ID: 506772
URI: http://eprints.soton.ac.uk/id/eprint/506772
ISSN: 0105-4538
PURE UUID: 7d073a19-d4e4-49ed-b70b-37ae424a454a
Catalogue record
Date deposited: 18 Nov 2025 17:39
Last modified: 19 Nov 2025 02:40
Export record
Altmetrics
Contributors
Author:
Jocelyne Just
Author:
Hendrik Nolte
Author:
Ole Holm Hels
Author:
Andrzej Emeryk
Author:
Carmen Vidal
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics